Skip to main content

Psychotic Disorders clinical trials at UCSD
4 in progress, 2 open to eligible people

  • Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

    open to eligible people ages 18-50

    This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory learning.

    San Diego, California

  • Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness

    open to eligible people ages 18-70

    Approximately 60 chronic smokers with bipolar disorder, schizophrenia or schizoaffective disorder who are motivated to try to quit smoking will be randomized to receive smoking cessation treatment with the FDA-approved medication, varenicline, delivered either a) at its standard dose and titration schedule (half of the participants) versus b) at a lower dose and slower titration schedule (the other half), for 12 weeks. All smokers will choose a target quit date sometime between 8 to 35 days after starting the medication. All participants will receive ten 30-minute sessions of a behavioral treatment called Acceptance and Commitment Therapy (ACT). Participants will be followed for an additional 12 weeks off study medication. The major endpoint is the feasibility of combining ACT with the different dosing strategies. Investigators will also conduct a blood test that measures the breakdown of nicotine in the body to explore whether that measure influences treatment response and side effects.

    La Jolla, California

  • Mobile CBT for Negative Symptoms

    Sorry, not yet accepting patients

    This randomized controlled clinical trial will test a combined group contact plus mobile CBT-informed skills training intervention targeting defeatist attitudes in consumers with schizophrenia in comparison to a supportive contact control group in order to change motivational negative symptoms linked to defeatist attitudes.

  • Mobile-Assisted Cognitive Behavior Therapy for Negative Symptoms in Schizophrenia

    Sorry, in progress, not accepting new patients

    This clinical trial will test a combined group therapy plus mobile cognitive behavioral therapy intervention targeting defeatist attitudes in consumers with schizophrenia in order to change motivational negative symptoms linked to defeatist attitudes.

Last updated: